Complete response to CAR T-cell therapy reported in RRMM patient
A first patient with relapsed/refractory multiple myeloma (RRMM) treated with CT0590, Carsgen Therapeutics’ CAR T-cell therapy, showed a complete response to the…
Myeloma
Researchers generate plasma cell dataset to aid myeloma diagnosis
Researchers in Brazil have developed a large dataset of cells taken from the bone marrow of people with multiple myeloma (MM) and other blood…
Sarclisa approved in EU for adults new to MM and transplant ineligible
Regulators in the European Union (EU) have approved Sarclisa (isatuximab) in combination with standard-of-care medications for adults newly diagnosed with multiple myeloma who…
AbbVie, Simcere Zaiming partner on myeloma treatment SIM0500
Abbvie is teaming up with China-based company Simcere Zaiming to advance the development of SIM0500, Simcere’s experimental treatment for multiple myeloma that’s…
Under-the-skin Sarclisa found as effective as approved formulation
A subcutaneous, or under-the-skin, formulation of Sarclisa (isatuximab) is just as effective as the approved intravenous (into-the-vein) version of the therapy at controlling treatment-resistant…
Minimal residual disease is potential early outcome measure in myeloma
Minimal residual disease or MRD — defined as a very small number of cancer cells that remain in the body during or after treatment —…
Cell therapy anito-cel shows promise for hard-to-treat RRMM
Most people with relapsed or refractory multiple myeloma (RRMM) given the cell therapy anitocabtagene autoleucel — known as anito-cel — in a Phase 2…
Carvykti delays myeloma symptom worsening, per Phase 3 trial data
The cell therapy Carvykti (ciltacabtagene autoleucel) — approved earlier this year as a second-line treatment for people with multiple myeloma — was shown to delay…
New atlas details immune cell changes as disease progresses
Researchers in Belgium have developed an atlas to mark changes in distinct types of immune cells during multiple myeloma’s  progression. Their work, in…
FDA to review combinations of Blenrep for multiple myeloma
The U.S. Food and Drug Administration (FDA) will review GSK’s request to approve Blenrep (belantamab mafodotin) as part of a combination treatment for adults…
